Literature DB >> 20437181

A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis.

J Furby1, T Hayton, D Altmann, R Brenner, J Chataway, K J Smith, D H Miller, R Kapoor.   

Abstract

MRI measures of tissue atrophy within the central nervous system may reflect the neurodegenerative process which underpins the progressive phase of multiple sclerosis (MS). There has been limited longitudinal investigation of MRI-detected atrophy in secondary progressive MS. This study includes 56 subjects with secondary progressive MS. Subjects were followed up for 2 years and MRI analysis was conducted at 12 month intervals using the following measures: (1) whole brain (WB) volume change; (2) grey and white matter (WM) volumes; (3) central brain volume; (4) upper cervical spinal cord (SC) area; (5) T2 lesion volumes. Clinical measures included the Expanded Disability Status Scale and the MS Functional Composite. All volumetric MRI measures were assessed for sensitivity, responsiveness, reliability and correlation with disability. The mean annual atrophy rate of WB was 0.59% per year and this was the most responsive atrophy measure assessed. Grey matter (GM) atrophy (-1.18% per year) was greater and more responsive than WM atrophy (0.12% per year). The SC demonstrated the highest atrophy rate at 1.63% per year. WB, GM and SC atrophy all correlated with change in the Multiple Sclerosis Functional Composite z score (r = 0.35, 0.42, 0.34), and GM atrophy was the only correlate of change in the 9 Hole Peg Test and Paced Auditory Serial Addition Test performance. None of the MRI measures correlated with Expanded Disability Status Score progression. Measures of WB, GM and SC atrophy all have attributes for use as surrogate markers in secondary progressive MS trials and improvement in the reliability of the GM and SC volume measurements may enhance these further.

Entities:  

Mesh:

Year:  2010        PMID: 20437181     DOI: 10.1007/s00415-010-5563-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans.

Authors:  P A Freeborough; N C Fox; R I Kitney
Journal:  Comput Methods Programs Biomed       Date:  1997-05       Impact factor: 5.428

2.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

3.  Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.

Authors:  C Bjartmar; G Kidd; S Mörk; R Rudick; B D Trapp
Journal:  Ann Neurol       Date:  2000-12       Impact factor: 10.422

4.  Gray matter atrophy in multiple sclerosis: a longitudinal study.

Authors:  Elizabeth Fisher; Jar-Chi Lee; Kunio Nakamura; Richard A Rudick
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

5.  Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.

Authors:  X Lin; C R Tench; B Turner; L D Blumhardt; C S Constantinescu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

6.  Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

Authors:  M Tiberio; D T Chard; D R Altmann; G Davies; C M Griffin; W Rashid; J Sastre-Garriga; A J Thompson; D H Miller
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

7.  Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study.

Authors:  L Ramió-Torrentà; J Sastre-Garriga; G T Ingle; G R Davies; V Ameen; D H Miller; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

8.  Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Authors:  Catherine M Dalton; Declan T Chard; Gerard R Davies; Katherine A Miszkiel; Dan R Altmann; Kryshani Fernando; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Brain       Date:  2004-03-03       Impact factor: 13.501

9.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.

Authors:  Declan T Chard; Geoffrey J M Parker; Colette M B Griffin; Alan J Thompson; David H Miller
Journal:  J Magn Reson Imaging       Date:  2002-03       Impact factor: 4.813

View more
  18 in total

1.  Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis.

Authors:  T Hayton; J Furby; K J Smith; D R Altmann; R Brenner; J Chataway; K Hunter; D J Tozer; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2011-08-24       Impact factor: 4.849

2.  A longitudinal MRI study of cervical cord atrophy in multiple sclerosis.

Authors:  Paola Valsasina; Maria A Rocca; Mark A Horsfield; Massimiliano Copetti; Massimo Filippi
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

Review 3.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

4.  Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.

Authors:  F X Aymerich; C Auger; J Alonso; M Alberich; J Sastre-Garriga; M Tintoré; X Montalban; A Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-28       Impact factor: 3.825

5.  RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.

Authors:  Adam M Kruszewski; Gautam Rao; Alexandru Tatomir; Daniel Hewes; Cosmin A Tegla; Cornelia D Cudrici; Vingh Nguyen; Walter Royal; Christopher T Bever; Violeta Rus; Horea Rus
Journal:  Exp Mol Pathol       Date:  2015-09-25       Impact factor: 3.362

6.  Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine.

Authors:  T Hayton; J Furby; K J Smith; D R Altmann; R Brenner; J Chataway; K Hunter; D J Tozer; D H Miller; R Kapoor
Journal:  J Neurol       Date:  2011-09-09       Impact factor: 4.849

7.  Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.

Authors:  Inga T Hagström; Ruth Schneider; Barbara Bellenberg; Anke Salmen; Florian Weiler; Odo Köster; Ralf Gold; Carsten Lukas
Journal:  J Neurol       Date:  2017-06-09       Impact factor: 4.849

8.  Power estimation for non-standardized multisite studies.

Authors:  Anisha Keshavan; Friedemann Paul; Mona K Beyer; Alyssa H Zhu; Nico Papinutto; Russell T Shinohara; William Stern; Michael Amann; Rohit Bakshi; Antje Bischof; Alessandro Carriero; Manuel Comabella; Jason C Crane; Sandra D'Alfonso; Philippe Demaerel; Benedicte Dubois; Massimo Filippi; Vinzenz Fleischer; Bertrand Fontaine; Laura Gaetano; An Goris; Christiane Graetz; Adriane Gröger; Sergiu Groppa; David A Hafler; Hanne F Harbo; Bernhard Hemmer; Kesshi Jordan; Ludwig Kappos; Gina Kirkish; Sara Llufriu; Stefano Magon; Filippo Martinelli-Boneschi; Jacob L McCauley; Xavier Montalban; Mark Mühlau; Daniel Pelletier; Pradip M Pattany; Margaret Pericak-Vance; Isabelle Cournu-Rebeix; Maria A Rocca; Alex Rovira; Regina Schlaeger; Albert Saiz; Till Sprenger; Alessandro Stecco; Bernard M J Uitdehaag; Pablo Villoslada; Mike P Wattjes; Howard Weiner; Jens Wuerfel; Claus Zimmer; Frauke Zipp; Stephen L Hauser; Jorge R Oksenberg; Roland G Henry
Journal:  Neuroimage       Date:  2016-04-01       Impact factor: 6.556

Review 9.  Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.

Authors:  Timothy Vollmer; Lynn Huynh; Caroline Kelley; Philip Galebach; James Signorovitch; Allitia DiBernardo; Rahul Sasane
Journal:  Neurol Sci       Date:  2015-11-04       Impact factor: 3.307

10.  Systemic complement profiling in multiple sclerosis as a biomarker of disease state.

Authors:  G Ingram; S Hakobyan; C L Hirst; C L Harris; S Loveless; J P Mitchell; T P Pickersgill; N P Robertson; B P Morgan
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.